Page 142 - 《中国药房》2024年12期

1916-1927. three species[J]. Diabetes，2012，61（5）：1243-1249.
[27] BORNER T，WORKINGER J L，TINSLEY I C，et al. [38] GIER B，MATVEYENKO A V，KIRAKOSSIAN D，et al.
Corrination of a GLP-1 receptor agonist for glycemic Chronic GLP-1 receptor activation by exendin-4 induces
control without emesis[J]. Cell Rep，2020，31（11）： expansion of pancreatic duct glands in rats and accelerates
107768. formation of dysplastic lesions and chronic pancreatitis in
[28] GABERY S，SALINAS C G，PAULSEN S J，et al. Sema‐ the KRAS（G12D）mouse model[J]. Diabetes，2012，61
glutide lowers body weight in rodents via distributed neu‐ （5）：1250-1262.
ral pathways[J]. JCI Insight，2020，5（6）：e133429. [39] MONAMI M，NREU B，SCATENA A，et al. Safety issues
[29] HJERPSTED J B，FLINT A，BROOKS A，et al. Semaglu‐ with glucagon-like peptide-1 receptor agonists（pancreati‐
tide improves postprandial glucose and lipid metabolism， tis，pancreatic cancer and cholelithiasis）：data from ran‐
and delays first-hour gastric emptying in subjects with domized controlled trials[J]. Diabetes Obes Metab，2017，
obesity[J]. Diabetes Obes Metab，2018，20（3）：610-619. 19（9）：1233-1241.
[30] FRIEDRICHSEN M，BREITSCHAFT A，TADAYON S， [40] HE L Y，WANG J L，PING F，et al. Association of
et al. The effect of semaglutide 2.4 mg once weekly on glucagon-like peptide-1 receptor agonist use with risk of
energy intake，appetite，control of eating，and gastric emp- gallbladder and biliary diseases：a systematic review and
tying in adults with obesity[J]. Diabetes Obes Metab， meta-analysis of randomized clinical trials[J]. JAMA In‐
2021，23（3）：754-762. tern Med，2022，182（5）：513-519.
[31] GUTZWILLER J P，HRUZ P，HUBER A R，et al. [41] NAUCK M A，MUUS GHORBANI M L，KREINER E，et
Glucagon-like peptide-1 is involved in sodium and water al. Effects of liraglutide compared with placebo on events
homeostasis in humans[J]. Digestion，2006，73（2/3）： of acute gallbladder or biliary disease in patients with type
142-150. 2 diabetes at high risk for cardiovascular events in the
[32] WEGEBERG A L，HANSEN C S，FARMER A D，et al. LEADER randomized trial[J]. Diabetes Care，2019，42
Liraglutide accelerates colonic transit in people with type （10）：1912-1920.
1 diabetes and polyneuropathy：a randomised，double- [42] SMITS M M，TONNEIJCK L，MUSKIET M H，et al. Bi-
blind，placebo-controlled trial[J]. United European Ga- liary effects of liraglutide and sitagliptin，a 12-week ran‐
stroenterol J，2020，8（6）：695-704. domized placebo-controlled trial in type 2 diabetes patients
[33] YANG Z，LV Y H，YU M，et al. GLP-1 receptor agonist- [J]. Diabetes Obes Metab，2016，18（12）：1217-1225.
associated tumor adverse events：a real-world study from [43] MARZIONI M，ALPINI G，SACCOMANNO S，et al.
2004 to 2021 based on FAERS[J]. Front Pharmacol，2022， Exendin-4，a glucagon-like peptide 1 receptor agonist，
13：925377. protects cholangiocytes from apoptosis[J]. Gut，2009，58
[34] TRUJILLO J. Safety and tolerability of once-weekly GLP- （7）：990-997.
1 receptor agonists in type 2 diabetes[J]. J Clin Pharm [44] COSKUN T，SLOOP K W，LOGHIN C，et al. LY3298176，
Ther，2020，45（Suppl. 1）：43-60. a novel dual GIP and GLP-1 receptor agonist for the treat‐
[35] NREU B，DICEMBRINI I，TINTI F，et al. Pancreatitis ment of type 2 diabetes mellitus：from discovery to clini‐
and pancreatic cancer in patients with type 2 diabetes cal proof of concept[J]. Mol Metab，2018，18：3-14.
treated with glucagon-like peptide-1 receptor agonists：an [45] FRÍAS J P，DAVIES M J，ROSENSTOCK J，et al. Tir-
updated meta-analysis of randomized controlled trials[J]. zepatide versus semaglutide once weekly in patients with
Minerva Endocrinol，2023，48（2）：206-213. type 2 diabetes[J]. N Engl J Med，2021，385（6）：503-515.
[36] ARODA V R，ABERLE J，BARDTRUM L，et al. Efficacy [46] BETTGE K，KAHLE M，ABD EL AZIZ M S，et al. Occur-
and safety of once-daily oral semaglutide 25 mg and 50 rence of nausea，vomiting and diarrhoea reported as ad‐
mg compared with 14 mg in adults with type 2 diabetes verse events in clinical trials studying glucagon-like pep‐
（PIONEER PLUS）：a multicentre，randomised，phase 3b tide-1 receptor agonists：a systematic analysis of published
trial[J]. Lancet，2023，402（10403）：693-704. clinical trials[J]. Diabetes Obes Metab，2017，19（3）：
[37] NYBORG N C，MØLCK A M，MADSEN L W，et al. The 336-347.
human GLP-1 analog liraglutide and the pancreas：evi‐ （收稿日期：2024-01-31 修回日期：2024-05-13）
dence for the absence of structural pancreatic changes in （编辑：孙 冰）

· 1544 · China Pharmacy 2024 Vol. 35 No. 12 中国药房 2024年第35卷第12期